Anika Therapeutics (ANIK) Stock Analysis & AI Equity Report

Medical - Devices USD Explore free reports

Anika Therapeutics (ANIK) overview

Anika Therapeutics (ANIK) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 113m and operating profit of USD -11.1m; the year-end share price was 9.61 USD and market capitalisation was USD 133m. Anika Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Anika Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 143mFY 2025
Share price9.61 USDFY 2025 year end
RevenueUSD 113mFY 2025
Operating profitUSD -11.1mFY 2025
Net earningsUSD -10.9mFY 2025
Market capitalisationUSD 133mFY 2025 year end

About Anika Therapeutics

Anika Therapeutics develops products using proprietary hyaluronic acid technology, with a focus on osteoarthritis pain management and regenerative solutions in orthopedics. Its portfolio includes single- and multi-injection viscosupplement products for osteoarthritis pain relief, generally administered in an office setting, and a scaffold system designed for rotator cuff and other tendon repairs. In the United States, Johnson & Johnson MedTech markets its Monovisc and Orthovisc products.

Generate the Anika Therapeutics report

Anika Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Anika Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Anika Therapeutics

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.